Search

Author/Creator Flaherty, Lawrence

1. 312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition. (9th November 2020)

Authors:
Tarhini, Ahmad; Kang, Ni; Lee, Sandra; Stephen Hodi, F; Cohen, Gary; Hamid, Omid; Hutchins, Laura; Sosman, Jeffrey; Kluger, Harriett; Eroglu, Zeynep; Koon, Henry; Lawrence, Donald; Kendra, Kari; Minor, David; Lee, Carrie; Albertini, Mark; Flaherty, Lawrence; Petrella, Teresa; Striecher, Howard; S...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A339
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01). (6th November 2014)

Authors:
Clark, Joseph; Flaherty, Lawrence; Ernstoff, Marc; Koon, Henry; Milhem, Mohammed; Militello, Gerald; Agarwala, Sanjiv; Curti, Brendan; Cranmer, Lee; Lao, Christopher D; Logan, Theodore F; Lutzky, Jose; Rudrapatna, Venkatesh; Daniels, Gregory; Taback, Bret; Aung, Sandra; Lowder, James; Lawson, David
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. (1st January 2021)

Authors:
Hasanov, Merve; Milton, Denái R.; Sharfman, William H.; Taback, Bret; Cranmer, Lee D.; Daniels, Gregory A; Flaherty, Lawrence; Hallmeyer, Sigrun; Milhem, Mohammed; Feun, Lynn; Hauke, Ralph; Doolittle, Gary; Gregory, Nancy; Patel, Sapna
Journal:
Oncoimmunology
Issue:
Volume 10:Number 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02). (6th November 2014)

Authors:
Patel, Sapna; Milhem, Mohammed; Hallmeyer, Sigrun; Daniels, Gregory; Cranmer, Lee; Taback, Bret; Flaherty, Lawrence; Aung, Sandra; Lowder, James; Sharfman, William
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer. Issue 6 (11th June 2021)

Authors:
Lum, Lawrence G.; Al-Kadhimi, Zaid; Deol, Abhinav; Kondadasula, Vidya; Schalk, Dana; Tomashewski, Elyse; Steele, Patricia; Fields, Kristie; Giroux, Melissa; Liu, Qin; Flaherty, Lawrence; Simon, Michael; Thakur, Archana
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 6(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗